KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Receivables (2016 - 2026)

Neogenomics filings provide 17 years of Change in Receivables readings, the most recent being $8.2 million for Q1 2026.

  • On a quarterly basis, Change in Receivables rose 1124.85% to $8.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $13.7 million, a 25.28% increase, with the full-year FY2025 number at $6.2 million, down 68.01% from a year prior.
  • Change in Receivables hit $8.2 million in Q1 2026 for Neogenomics, up from $4.2 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $9.1 million in Q1 2024 to a low of -$1.4 million in Q4 2023.
  • Median Change in Receivables over the past 5 years was $2.4 million (2025), compared with a mean of $3.1 million.
  • The widest YoY moves for Change in Receivables: up 1271.46% in 2023, down 118.3% in 2023.
  • Neogenomics' Change in Receivables stood at $7.7 million in 2022, then tumbled by 118.3% to -$1.4 million in 2023, then skyrocketed by 37.11% to -$888000.0 in 2024, then soared by 573.76% to $4.2 million in 2025, then soared by 94.49% to $8.2 million in 2026.
  • The last three reported values for Change in Receivables were $8.2 million (Q1 2026), $4.2 million (Q4 2025), and $2.4 million (Q3 2025) per Business Quant data.